| Title |
A predictive value of von Willebrand factor for early response to Bevacizumab therapy in recurrent glioma
|
|---|---|
| Published in |
Journal of Neuro-Oncology, March 2018
|
| DOI | 10.1007/s11060-018-2820-x |
| Pubmed ID | |
| Authors |
Andrea Pace, Chiara Mandoj, Anna Antenucci, Veronica Villani, Isabella Sperduti, Beatrice Casini, Mariantonia Carosi, Alessandra Fabi, Antonello Vidiri, Tatiana Koudriavtseva, Laura Conti |
| Abstract |
Bevacizumab (BV), a neutralizing monoclonal antibody against the vascular endothelial growth factor ligand, is recognized as a potent anti-angiogenic agent with antitumor activity. The aim of this single-center, retrospective, longitudinal study was to investigate the possible predictive value of baseline demographic, clinical and laboratory parameters for early 3-month response to BV therapy in patients with recurrent glioma. Forty-nine patients with recurrent glioma received BV at 10 mg/kg intravenously every 3 weeks alone or in association with chemotherapy were included in this study. Blood samples were collected from all patients before the first (baseline), the second and the third administration of BV. After 3 months of BV therapy, patients with partial response were defined as responders whereas patients with stable or progressive disease were defined as non-responders. The median overall follow-up was 8 months (range 1-73), the median overall survival (OS) was 8 months (95% CI 6-10) and the median progression free survival (PFS) was 4 months (95% CI 3-5). Thirty-five % of patients were responders and showed significantly lower von Willebrand factor (VWF) levels than non-responders at all sample times (p < .02 for all). Also, on multivariate analysis the baseline VWF value was the only predictor for an early response to BV therapy. Furthermore, D-dimer and prothrombin fragment 1+2 were predictive factors for OS while Karnofsky performance status resulted predictive for PFS. VWF antigen value is a possible predictive biomarker for an early 3-month response to BV therapy in recurrent glioma. |
X Demographics
The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Portugal | 1 | 33% |
| Australia | 1 | 33% |
| United States | 1 | 33% |
Demographic breakdown
| Type | Count | As % |
|---|---|---|
| Members of the public | 1 | 33% |
| Scientists | 1 | 33% |
| Science communicators (journalists, bloggers, editors) | 1 | 33% |
Mendeley readers
The data shown below were compiled from readership statistics for 14 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 14 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 2 | 14% |
| Student > Ph. D. Student | 2 | 14% |
| Unspecified | 1 | 7% |
| Student > Doctoral Student | 1 | 7% |
| Professor | 1 | 7% |
| Other | 2 | 14% |
| Unknown | 5 | 36% |
| Readers by discipline | Count | As % |
|---|---|---|
| Neuroscience | 2 | 14% |
| Medicine and Dentistry | 2 | 14% |
| Business, Management and Accounting | 1 | 7% |
| Unspecified | 1 | 7% |
| Biochemistry, Genetics and Molecular Biology | 1 | 7% |
| Other | 1 | 7% |
| Unknown | 6 | 43% |
Attention Score in Context
This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 30 March 2018.
All research outputs
#14,530,460
of 24,378,020 outputs
Outputs from Journal of Neuro-Oncology
#1,833
of 3,120 outputs
Outputs of similar age
#175,284
of 333,582 outputs
Outputs of similar age from Journal of Neuro-Oncology
#34
of 90 outputs
Altmetric has tracked 24,378,020 research outputs across all sources so far. This one is in the 39th percentile – i.e., 39% of other outputs scored the same or lower than it.
So far Altmetric has tracked 3,120 research outputs from this source. They receive a mean Attention Score of 4.4. This one is in the 39th percentile – i.e., 39% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 333,582 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 90 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 63% of its contemporaries.